The epidemiology of Lp-PLA2:: Distribution and correlation with cardiovascular risk factors in a population-based cohort

被引:78
作者
Persson, Margaretha [1 ]
Nilsson, Jan-Ake
Nelson, Jeanenne J.
Hedblad, Bo
Berglund, Goran
机构
[1] Malmo Univ Hosp, Dept Med, Malmo, Sweden
[2] GlaxoSmithKline, Dept Worldwide Epidemiol, Res Triangle Pk, NC USA
关键词
cardiovascular disease; epidemiology; Lp-PLA(2); risk factor;
D O I
10.1016/j.atherosclerosis.2006.02.016
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Lipoprotein-associated phospholipase A(2) (Lp-PLA(2)) is an enzyme that is produced by inflammatory cells (macrophages, T-lymphocytes and mast cells) and hydrolyzes oxidized phospholipids in LDL. Several epidemiology studies indicate that Lp-PLA(2) appears to be an independent marker of cardiovascular risk. This study was conducted to define the distribution of Lp-PLA(2) in a large population-based cohort and to determine associations between Lp-PLA(2) and other risk factors for CVD. The study group consisted of participants from the Malmo Diet and Cancer study (1992-1994). Lp-PLA(2) (activity and mass) was measured from samples obtained at baseline for 5402 participants (3167 women). A strong correlation was observed between Lp-PLA(2) activity and mass in this study (r = 0.57). Highest correlations were observed between Lp-PLA(2) activity and LDL (r=0.45) and LDL/HDL ratio (r=0.54) and a strong inverse correlation to HDL (r=-0.31). The correlations between Lp-PLA(2) mass and lipids were not as strong as the correlation between activity and lipids. Lp-PLA(2) activity and mass were correlated with increased ultrasound determined carotid intima-media thickness. We conclude that Lp-PLA(2) is strongly correlated with several cardiovascular risk factors, especially lipid fractions, and with the degree of carotid artery atherosclerosis. However, the measured variables accounted for only 19% and 35% of the variation in Lp-PLA(2) mass and activity respectively. (c) 2006 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:388 / 396
页数:9
相关论文
共 30 条
[1]   Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident coronary heart disease in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study [J].
Ballantyne, CM ;
Hoogeveen, RC ;
Bang, H ;
Coresh, J ;
Folsom, AR ;
Heiss, G ;
Sharrett, AR .
CIRCULATION, 2004, 109 (07) :837-842
[2]   DESIGN AND FEASIBILITY [J].
BERGLUND, G ;
ELMSTAHL, S ;
JANZON, L ;
LARSSON, SA .
JOURNAL OF INTERNAL MEDICINE, 1993, 233 (01) :45-51
[3]   A prospective evaluation of lipoprotein-associated phospholipase A2 levels and the risk of future cardiovascular events in women [J].
Blake, GJ ;
Dada, N ;
Fox, JC ;
Manson, JE ;
Ridker, PM .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2001, 38 (05) :1302-1306
[4]   Plasma PAF-acetylhydrolase in patients with coronary artery disease: results of a cross-sectional analysis [J].
Blankenberg, S ;
Stengel, D ;
Rupprecht, HJ ;
Bickel, C ;
Meyer, J ;
Cambien, F ;
Tiret, L ;
Ninio, E .
JOURNAL OF LIPID RESEARCH, 2003, 44 (07) :1381-1386
[5]   Association of lipoprotein-associated phospholipase A2 levels with coronary artery disease risk factors, angiographic coronary artery disease, and major adverse events at follow-up [J].
Brilakis, ES ;
McConnell, JP ;
Lennon, RJ ;
Elesber, AA ;
Meyer, JG ;
Berger, PB .
EUROPEAN HEART JOURNAL, 2005, 26 (02) :137-144
[6]   Lipoprotein-associated phospholipase A2, platelet-activating factor acetylhydrolase:: a potential new risk factor for coronary artery disease [J].
Caslake, MJ ;
Packard, CJ ;
Suckling, KE ;
Holmes, SD ;
Chamberlain, P ;
Macphee, CH .
ATHEROSCLEROSIS, 2000, 150 (02) :413-419
[7]  
Dada Nisha, 2002, Expert Rev Mol Diagn, V2, P17
[8]  
FRIEDEWALD WT, 1972, CLIN CHEM, V18, P499
[9]   Mechanisms of disease - Inflammation, atherosclerosis, and coronary artery disease [J].
Hansson, GK .
NEW ENGLAND JOURNAL OF MEDICINE, 2005, 352 (16) :1685-1695
[10]  
IRIBARREN C, 2005, ARTERIOSCL THROM VAS, V25, P1